EFFECT OF POSTTRANSPLANT METHOTREXATE, CYCLOSPORINE-A AND PREDNISOLONE ON GRAFT-REJECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

被引:0
|
作者
UHAREK, L [1 ]
GASSMANN, W [1 ]
FLEISCHHAUER, D [1 ]
WOTTGE, HU [1 ]
LOEFFLER, H [1 ]
MUELLERRUCHHOLTZ, W [1 ]
机构
[1] UNIV KIEL, DEPT INTERNAL MED 2, W-2300 KIEL 1, GERMANY
关键词
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Methotrexate, cyclosporin A and prednisolone have been shown to improve graft survival rates in solid organ transplantation. However, little is known concerning their capacity to promote lasting engraftment of allogeneic bone marrow. Therefore, we tested these agents in LEW rats receiving MHC-mismatched marrow after pretreatment with a myeloablative dose of busulfan plus different doses of total body irradiation (TBI). To avoid mortality due to graft-versus-host reaction (GHVR), F1(CAP x LEW) marrow was transferred. Hematological parameters were determined twice weekly to monitor engraftment and rejection. The pretreatment was lethal but not sufficiently immunosuppressive to ensure lasting engraftment in all animals. Thus, post-transplant immunosuppressive protocols could be evaluated for their capacity to improve engraftment rates. Standard clinical doses of methotrexate (0.25 mg/kg i.p. day 1, 3, 6, 11, 18, 25), cyclosporin A (10 mg/kg orally day 0-28) and prednisolone (1 mg/kg i.p day 0-28) were administered and proved to be of nearly equivalent toxicity in our system. All three agents failed to allow engraftment after busulfan alone. After additional conditioning with 1.5 Gy of TBI, methotrexate and cyclosporin A reduced the rejection rate from 100% to 59% and 70%, respectively. When 3 Gy of TBI were added to busulfan, cyclosporin A and prednisolone were able to reduce the rejection rate from 67% to 33% and 39%, respectively, whereas 0.12 and 0.25 mg/kg methotrexate completely prevented graft rejections. After cessation of cyclosporin A therapy, late secondary rejections were frequently observed. These results demonstrate that postgrafting immunosuppression with protocols conventionally used for the prophylaxis of GVHR is able to facilitate lasting engraftment of MHC-mismatched bone marrow. According to our data the immunosuppressive potency of the Seattle methotrexate regimen is nearly equivalent to that of 1.5 Gy of TBI. Neither cyclosporin A nor prednisolone were as effective as methotrexate in our system.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [1] CYCLOSPORINE-A NEUROTOXICITY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    FIORANI, L
    BANDINI, G
    DALESSANDRO, R
    ROSTI, G
    BONE MARROW TRANSPLANTATION, 1994, 14 (01) : 175 - 176
  • [2] COMPARISON OF IMMUNOSUPPRESSIVE AGENTS FOR PREVENTION OF GRAFT-REJECTION IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
    UHAREK, L
    GASSMANN, W
    FLEISCHHAUER, D
    WOTTGE, HU
    LOEFFLER, H
    MULLERRUCHHOLTZ, W
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 3042 - 3044
  • [3] PREVENTION OF GRAFT-REJECTION FOLLOWING BONE-MARROW TRANSPLANTATION
    GALE, RP
    HO, W
    FEIG, S
    CHAMPLIN, R
    TESLER, A
    ARENSON, E
    LADISH, S
    YOUNG, L
    WINSTON, D
    SPARKES, R
    FITCHEN, J
    TERRITO, M
    SARNA, G
    WONG, L
    PAIK, Y
    BRYSON, Y
    GOLDE, D
    FAHEY, J
    CLINE, M
    BLOOD, 1981, 57 (01) : 9 - 12
  • [4] GRAFT-REJECTION AFTER TRANSPLANTATION OF T-CELL-DEPLETED BONE-MARROW
    HERTENSTEIN, B
    ARNOLD, R
    BUNJES, D
    SCHMEISER, T
    WIESNETH, M
    HEIMPEL, H
    HEIT, W
    BLUT, 1986, 53 (03): : 187 - 188
  • [5] BONE-MARROW GRAFT-REJECTION PREVENTION
    FISCHER, A
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1987, 29 (03): : 193 - 193
  • [6] HEMATOPOIETIC AND IMMUNOLOGICAL RECONSTITUTION FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION USING METHOTREXATE OR CYCLOSPORINE-A AS GRAFT VERSUS HOST PROPHYLAXIS
    HAEN, M
    SCHNEIDER, EM
    OSTENDORF, P
    WERNET, P
    EXPERIMENTAL HEMATOLOGY, 1985, 13 : 103 - 103
  • [7] EFFECT OF DIFFERENT RADIATION SCHEDULES ON BONE-MARROW GRAFT-REJECTION
    PRENTICE, HG
    PATTERSON, J
    BRENNER, MK
    SKEGGS, D
    BRITISH JOURNAL OF RADIOLOGY, 1986, 59 (703): : 724 - 725
  • [8] PREVENTION OF GRAFT-REJECTION IN T-DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) - PRECLINICAL STUDIES
    FILIPOVICH, AH
    MALILAY, G
    LEVASSEUR, B
    CONDIE, RM
    SEVENICH, E
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 241 - 241
  • [9] PREVENTION OF GRAFT-REJECTION IN ALLOGENEIC BONE-MARROW TRANSPLANTATION .1. PRECLINICAL STUDIES WITH ANTITHYMOCYTE GLOBULINS
    MALILAY, GP
    SEVENICH, EA
    CONDIE, RM
    FILIPOVICH, AH
    BONE MARROW TRANSPLANTATION, 1989, 4 (01) : 107 - 112
  • [10] CYCLOSPORINE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
    RINGDEN, O
    TRANSPLANTATION, 1986, 42 (05) : 445 - 452